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Abstract 
VitaThreads LLC has recently developed an alternative to the current marketed 
suture that promotes a faster healing process with less induction of fibrotic tissue. The 
VitaThreads product, a fibrin microthread based suture, is composed of bovine derived 
fibrinogen and thrombin. To ensure patient safety and gain Federal Drug Administration 
(FDA) approval, a viral reduction process must be incorporated into fibrin microthread 
manufacturing to eliminate the risk of viral transmission in patients. The quality of the 
threads, including mechanical properties, need to be maintained through the reduction 
process to retain the ability to be implanted. A process was designed in which, thrombin 
and fibrinogen were initially treated separately at the liquid phase, thrombin was treated 
with an acid pH alteration and fibrinogen with a solvent detergent combination. Threads 
were then formed and underwent a secondary treatment utilizing a dry heat procedure. 
Viral reduction was validated against bacteriophage ΦX174 and quantified using a plaque 
assay. ΦX174 is commonly used in industry to mimic potential bovine derived viruses. 
The viral reduction of the acid pH, solvent/detergent precipitation and dry heat was 
greater than 6, 3.6, and greater than 2, respectively. The viral reduction process did not 
significantly alter the mechanical properties (ultimate tensile strength) of the sutures. The 
FDA does not issue a minimum reduction factor for approval, but these results 
demonstrate process efficiency that is likely to gain FDA approval. 
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1.0 Introduction 
Wound healing is a process in which the body repairs itself after a trauma. The 
process is broken down into six steps: rapid homeostasis, inflammation, proliferation and 
migration, angiogenesis, re-epithelialization, and synthesis [35]. Scar tissue may form in 
these steps and leave everlasting damage in the affected tissue. In the cosmetic industry, 
doctors cannot always limit the presence of scar tissue after a surgical procedure. Scar 
tissue is much weaker and less tensile than normal, healthy tissue, which can lead to pain 
and scar visibility on the skin [36].  
Sutures are utilized in many surgical procedures and commonly cause an 
inflammatory response at the wound-site, as well as permanent scarring after removal or 
degradation. VitaThreads uses bovine derived fibrinogen and thrombin to manufacture 
VitaSutures, a recently developed alternative to generic sutures, to reduce scarring in 
wound healing. This new suture reduces the formation of scar tissue, is less 
inflammatory, and more pliant than others on the market [5,6]. Despite the effectiveness 
of VitaSutures, they have not reached clinical trials due to lack of a purification system 
for viral reduction of the starting products. The use of bovine derived materials 
introduces concern of transmission of bovine-related viruses to the patient. To assure 
safety, the Federal Drug Administration (FDA) issues requirements for viral reduction, 
including an overall viral reduction of 1012 [34]. VitaThreads must meet these standards 
for their VitaSutures before moving into human clinical trials. The purpose of this Major 
Qualifying Project is to develop a method to remove bovine-related viruses from the 
VitaSutures.  
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2.0 Literature Review 
2.1 Introduction 
The literature review section provides an overview of the importance and methods 
currently employed to remove viruses in biological samples. In the context of the FDA, 
viral clearance requirements are introduced and are specific to the potential viruses in 
bovine derived materials. The major viruses found in bovine derived sources are 
categorized as enveloped or non-enveloped. This characteristic helps determine which 
purification method can be utilized.  
2.2 Fibrinogen and Thrombin pH and Temperature Stability 
Fibrin microthreads are an engineered skin regenerative suture aimed to reduce 
scarring during wound closing. As described in Cornwell et al., they are made from the 
co-extrusion of fibrinogen and thrombin [16]. Fibrinogen is a soluble protein that is 
convert by thrombin to insoluble fibrin strands forming a fibrin network. Thrombin 
cleaves the E domain on fibrinogen and allows the D and E domains to overlap and 
crosslink to form fibrin. The properties of these components are significant to the overall 
function of the sutures and must not be disrupted during purification. Fibrinogen is both 
temperature and pH sensitive and follows two steps of irreversible unfolding at different 
temperatures, influenced by pH (REFERENCE). At neutral pH, the D fragment will 
unfold at 57.7 °C and the E fragment at 96 °C. The conformation of both is essential to 
the development of fibrin microthreads. Additionally, at a pH of 3.5, the fibrinogen is 
slightly less stable at lower temperatures, while the opposite effect is seen at a pH around 
8.5 [1]. Thrombin, similar to fibrinogen, will denature at 60 °C and will not be able to 
function properly. Thrombin is more stable when heated in a dry solid state as compared 
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to a solution state [2]. Thrombin is in functional form from pH 5-10, but will precipitate 
at a pH of 5 or less [3]. These characteristics, in terms of pH and heat stability, of 
fibrinogen and thrombin were considered when designing the reduction system.  
2.3 VitaThreads Advantages and Formation 
The company VitaThreads manufactures fibrin microthreads. Fibrin microthreads, 
also referred to as VitaSutures, are a designed to be a premium product for physicians to 
use for patient wound closures. VitaThreads uses bovine derived fibrinogen and thrombin 
to manufacture VitaSutures. These bovine products are nearly identical in structure and 
conformation to their human counterparts [4]. VitaSutures are slightly more expensive 
that other skin closure products on the market, but reduces scar tissue formation in 
patients [5]. President and CEO of VitaThreads, Adam Collette, mentioned VitaSutures 
create a “less inflammatory, more pliant suture for patients to allow for a better outcome” 
[6]. They have demonstrated positive test results in the rat model and are supported by 
several physicians, including Dr. Frank P. Fechner of Harvard Medical School. However, 
VitaThreads cannot begin a phase I human clinical trial without FDA clearance. More 
specifically, the FDA has requirements for confirmed viral reduction before testing in 
humans.  
Initially bovine-derived fibrinogen and thrombin are obtained in powder form and 
need to be dissolved in HBSS. Once the liquid solutions of fibrinogen and thrombin are 
developed, 1ml of each solution is drawn up in a syringe and attached to an extrusion 
system. The extrusion system presses against the syringe pumps at a rate of 
0.236mm/min and thin tubing is used to draw out the threads in a pan filled with HEPES 
buffer solution. Typically each batch of fibrin microthreads made from these solutions 
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creates approximately thirty threads. The threads form in the shallow buffer solution and 
are removed from the pan using tweezers after approximately ten minutes. Once removed 
the threads are hung to dry on a box overnight and removed the following day and placed 
into aluminum foil for storage if future testing is required.  
2.4 The Impact of Viral Reduction 
Biological samples, derived from animal sources, may contain infectious agents 
that are harmful to humans. If a patient is exposed to a product that has not been properly 
purified, they are at risk of contracting diseases due to contamination. For example, the 
company, Bayer, did not properly sterilize their blood products for hemophiliac patients. 
These products contained Human Immunodeficiency Virus (HIV), causing thousands of 
patients over three decades to contract HIV and later die of Aquired Immunodeficiency 
Syndrome (AIDS) [32]. There are not only scientific reasons to purify products, but also 
ethical reasons to ensure patients do not contract any life threatening diseases. Certain 
viruses are more prevalent in human-derived products than other species, including 
hepatitis A (HAV), hepatitis B (HBV), human immunodeficiency (HIV), and parvovirus 
(B19) [7].  
2.5 Bovine Viral Contamination 
Since fibrinogen and thrombin are bovine derived, they have the potential to 
contain viruses specific to the bovine source. These viruses can be transmitted directly to 
humans and cause illnesses, known as zoonotic diseases. In 2012, 13 of the 56 identified 
zoonotic diseases killed an estimated 2.2 million people. Cattle, along with chickens and 
pigs, are the main sources causing these illnesses in humans [8]. While cattle can be 
infected with different agents, there are specific viruses of concern  for human 
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contraction, such as bovine viral diarrhea (BVD), infectious bovine Rhinotracheitis 
(IBR), bluetongue (BTV), and parapoxvirus (PPV) [33]. Additionally, researchers at UC 
Berkeley identified a correlation between bovine leukemia virus (BLV) and human breast 
cancer; this was determined because milk tanks were not free of viral contamination and 
many humans who drank that milk later developed breast cancer [9].  
2.6 Bovine Products on the Market 
There are multiple bovine derived medical therapies available for human use. 
Trasylol (Aprotinin) is a proteinase inhibitor obtained from bovine lung, used in patients 
undergoing cardiopulmonary bypass surgeries to reduce inflammation and bleeding. The 
drug was discontinued in 2008 due to associated risks of kidney failure, heart attack, 
heart failures, and strokes. Although anaphylactic reactions were a potential concern from 
the product being of animal origin, bovine related reasons were not a factor to 
discontinue the drug [11]. The company, Lescarden, offers a bovine derived product, 
referred to as Catrix. Catrix is FDA approved for wound closing applications and is 
currently in testing for skin care and bio-cartilage applications. In wound closing, it is 
approved for pressure/stasis/diabetic ulcers, first/second degree burns, post-surgical 
incisions, radiation dermatitis and more [12]. Another product on the market, is bovine 
collagen hydrolysate. It is synthesized from the different forms of collagen and contains a 
high amino acid content to supplement decayed protein [13]. Bovine insulin is also used 
for human healthcare [14]. The aforementioned shows that FDA clearance of bovine-
derived materials is achievable through the proper purification system to remove 
infectious disease agents, such as viruses.  
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2.7 FDA Requirements 
The FDA issues many requirements to ensure the public safety who utilize 
healthcare products. In the case of viral reduction, they have precise specifications to 
approve products for use. They assess the appropriateness of viruses used, design of 
testing, log reduction factor, potential effects of variation in process parameters, and 
limitations of assays used for detection.  .
2.7.1 Viruses Tested 
When analyzing the validity of the viral reduction system, the FDA considers 
which viruses were tested. The FDA provides a list of major bovine derived viruses that 
must be eliminated, but does not require every virus be tested. Instead, manufacturers can 
test one virus that overlaps with another based on their similar characteristics and 
research showing how they will respond to certain treatments. The FDA classifies the 
viruses chosen for testing into three types: relevant, model-specific, and model-
nonspecific. Relevant viruses are within the same species; model-specific viruses are 
related (usually the same genus/family); and model-nonspecific viruses are random 
viruses in nature with a wide range of physico-chemical properties. The purpose of the 
model-nonspecific type is to demonstrate protection against random viruses in nature that 
could unexpectedly contaminate the sample.  
The FDA recognizes it may be difficult to test certain viruses due to safety 
concerns. For example, HIV is categorized as a biosafety level 2 (BSL-2) virus and 
requires certain safety precautions that may not be available at all facilities. In this case, 
the testing party could use attenuated HIV or bacteriophages, which are accepted by the 
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FDA as HIV surrogates. An attenuated virus has altered nucleic acid that makes it less 
dangerous to humans if transmitted. Bacteriophages are a type of virus that infect bacteria 
and are not harmful to humans. Bacteriophages are becoming increasingly popular in 
viral reduction tests due to their similarity in physiochemical properties and sizes 
compared to their mammalian viral counterparts. They are also easier and cheaper to test 
with little safety concerns for humans [40]. The FDA states, “the choice and number of 
viruses used will be influenced by the quality and characterization of the [material 
source] and the production process,” which includes mammalian viruses, attenuated 
viruses, and bacteriophages. After determining which viruses to test and exposing them to 
steps of the reduction system, there must be an “efficient and reliable assay for detection 
of every stage of viral reduction.” Overall, the FDA issues these requirements to ensure 
public safety in potentially dangerous consumer products and healthcare treatments.  
2.7.2 FDA Required Viruses for Reduction 
The FDA requires bovine derived products to acknowledge and remove specific 
viruses that could potentially contaminate them. These viruses can be broken down into 
bovine-related and non-bovine related viruses. In total, there are fourteen viruses of 
concern and each virus has their own specific characteristics that can impact the viral 
reduction process.  
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Table&1:&FDA&Required&Viruses&for&Reduction&in&Bovine&Derived&Products&[15,&17,&33]&
 
 In Table 1, each virus is distinguished based on different characteristics. Most 
importantly, these viruses were categorized as enveloped or non-enveloped. The 
enveloping characteristic becomes important when investigating which potential viral 
reduction techniques to apply. Many viral reduction techniques are either applicable to 
only enveloped viruses or a combination of enveloped and non-enveloped viruses. 
Depending on the size of the virus, it allows for the necessary filter to be determined and 
implemented for viral reduction Furthermore, viruses can be categorized into their genus, 
which groups them with other viruses with similar properties. Using the genus 
characterization it will be possible to remove all viruses grouped under that specific 
genus [18]. Lastly, nucleic acid type becomes important when quantifying viral 
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concentration after applying the desired virus reduction techniques using polymerase 
chain reaction (PCR). 
2.7.3 FDA Reduction Specifications and Testing  
In testing the efficacy of the viral reduction system, the FDA requires spiking of 
pre-products with a known viral concentration. The initial amount is then compared to the 
concentration after each individual step. A log reduction factor is calculated for each step. 
Typically, a reduction factor greater than 4 for an individual step is considered effective 
[34]. 
10푅푖 = ! (푣! ∗ 10푎!)!(푣! ∗ 10푎!)  
푤ℎ푒푟푒!푥 = ! (푣! ∗ 10푎!)!(푣! ∗ 10푎!)  
푅푖 = 푙표푔!"(푥) 
Ri is the calculated log reduction factor; v1 is the original sample volume (liters); v2 is the 
final sample volume (liters); 10a1 is the initial viral titer; 101 is the final viral titer.  
The reduction factor can be added together after each step to estimate a total 
reduction factor for the entire system. However, as the FDA describes, this may 
overestimate the effectiveness of the system because of potential similarity in two or 
more reduction steps. For example, if reduction steps A and B each reduce viral 
contamination by 90% independently, theoretically, only 1% of the virus should remain 
after moving a sample through both these steps. This is not necessarily the case in 
practice, because if step B is similar to step A, it may not remove the viruses that step A 
could not.  
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The FDA also has standards for low viral concentrations to test reduction. This is 
usually the case in the actual product process where the pre-product is not spiked with 
viruses. In some cases, the FDA requires an estimation of the remaining virus based on 
the equation below.  
푃 = 푉 − 푣푉 ∗ 푛 ) 
푖푓!푉 ≫ 푣 
푃 = 푒!푐∗푣 
P represents the probability the sample contains viruses; V is the overall volume 
used (liters); v is the volume of sample used (liters), and n is the number of infectious 
particles distributed in V. When a portion of the whole bulk is assayed for viruses, the P 
value above shows the probability that specific sample contains viruses based on volume 
distribution. This metric is required to ensure manufacturers test enough of the bulk 
material that is representative of the entire production bulk. With both the probability and 
log reduction factors, the FDA also wants manufactures to explain and justify their 
approaches for evaluating clearance and to provide two independent studies supporting 
the results.  
2.8 Enveloped vs. Non-Enveloped Viruses  
Viruses are intracellular pathogens that are composed of a wide range of different 
properties, including genetic material, function, structure, and more. These pathogens 
consist of a wide range of cellular molecules that enable their propagation [19]. One 
classification of viruses is based on their virion structure being enveloped or non-
enveloped. Enveloped viruses have a lipid membrane and the structure is broken down 
into two components: the membrane and the core. The membrane is composed of 
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glycoprotein spikes, a membrane or matrix protein, and a lipid bilayer. The core of this 
structure either contains an icosahedral capsid or a helical nucleocapsid [20]. The main 
difference between non-enveloped and enveloped viruses is non-enveloped viruses to do 
not have a lipid membrane encapsulating the nucleic acids. The structures of non-
enveloped viruses are icosahedral capsids that are made up of repeating subunits [20]. 
This type of virus propagates through cell lysis [19]. These components are important to 
consider when determining reduction methods. 
2.9 Reduction Techniques for Enveloped Viruses 
There are three different types of reduction techniques that are solely successful in 
the reduction of enveloped viruses, which are acid, pH, and solvent/detergent. Although 
each of these methods functions differently to remove the viruses, the fibrinogen and 
thrombin components cannot be denatured, damaged, or removed. If this occurs, the 
fibrin microthread VitaSutures will not form. This will be considered when choosing and 
modifying the techniques for reduction of enveloped viruses.  
2.9.1 Chemical Treatments  
 An acidic pH can be used to disrupt the lipid envelope of a virus, which ultimately 
removes it and destroys the virus [21]. This procedure is typically an easy process to 
complete and requires a pH less than 6.0, with most studies confirming that the greatest 
viral reduction occurred at a pH of 4.0 [21]. A study completed by Valdes et al. used a 
combination of chromatography, low pH, and heating, and concluded that almost all 
enveloped viruses were inactivated and brought to undetectable levels when exposed to a 
pH of 3.0 [22]. Another study showed that approximately 90% of the enveloped viruses 
were removed at a pH of 6.0 [23]. When looking at bovine specific viruses, virus 
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reduction was also completed using 70% Ethanol or 4% NaOH by volume. The use of 
70% Ethanol inactivated viruses after 30 minutes, while 4% NaOH removed viruses after 
only 5 minutes [15]. Depending on the viral characteristics, different pH levels need to be 
tested to determine the most effective level. Other key factors to take into consideration 
were the homogeneity of the acid solution, and the temperature and incubation time the 
product is exposed to the acidic pH [24,21]. Because proteins and enzymes are sensitive 
to pH changes, this may result in denatured fibrinogen and thrombin.  
2.9.2 Solvent/Detergent  
Solvents and detergents are organic mixtures that disrupt the lipid membranes of 
viruses, making this method inapplicable to non-enveloped viruses [24]. This disruption 
does not allow viruses to bind and infect cells [21]. These solvent/detergent reagents, 
such as Triton X-100 and Tri-n-Butyl Phosphate (TNBP), were added to the product for 
four to six hours, which includes two different incubation periods to ensure that the 
entirety of the product is exposed to the reagents [21]. This process occurs at 
temperatures ranging from 24°C to 30°C and the viruses are typically removed in just a 
few minutes [24,21]. The reagents must be combined thoroughly to create a 
homogeneous mixture. They generally do not cause protein denaturation during the 
process, which ensures proteins maintain functionality [24]. Importantly, after the 
product is already solvent/detergent treated, this method can be used in combination other 
techniques such as with nanofiltration and heat treatments [25].  
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2.10 Reduction Techniques for Enveloped and Non-Enveloped Viruses  
Specific reduction techniques can be used in combination with those mentioned 
above to ensure the reduction of some non-enveloped viruses, along with enveloped 
viruses.  
2.10.1 Nanofiltration 
Nanofiltration is method in which viruses are prevented from crossing the 
membrane filter. Nanofiltration segregates proteins and viruses based on their size. The 
components larger than the specified pore size are retained and all others are able to flow 
through. These filters have small pore sizes between 15 and 45 nanometers [24]. The 
method of nanofiltration is a simple task to carry out and does not require the use of any 
extensive equipment [24]. When using this method, the protein solution volume, flow 
rate, filter integrity, protein concentration, and pressure can be altered to best fit the given 
experiment [24,21]. Studies have shown that nanofiltration is typically able to remove 4 
to 6 logs of a variety of viruses in plasma solutions [24]. The nanofiltration process has 
removed many non-enveloped viruses that are resistant to current inactivation methods 
[24]. 90-95% of proteins have shown full recovery and upheld biological activity when 
subjected to nanofiltration [24]. To ensure protein recovery and functionality, the 
conditions at which this step is processed must be constant and mild with regards to pH, 
temperature, osmolality, and pressure. Nanofiltration does not have a specific length of 
time required to carry it out and it can be implemented during the manufacturing process 
or during the final purification process before thread formation [24]. 
 Currently, nanofiltration techniques are used on human derived thrombin and 
fibrinogen. Methods for the treatment of solvent-detergent treated/dry-heated fibrinogen 
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and solvent-detergent-treated thrombin has also been performed [25]. Nanofiltration is a 
viable option for the reduction of bovine viruses in fibrinogen and thrombin solutions.  
2.10.2 Heating Methods 
2.10.2.1 Pasteurization  
 Pasteurization must occur in the liquid phase and begins by filtering the solution 
to ensure the reduction of particles that could trap and stabilize viruses [24,21]. Filter size 
depends on the characteristics of the protein and the potential viruses that could be in the 
source.  After filtering, stabilizers are added to the product solutions, such as amino acids, 
sugars, or citrate [21], to avoid protein denaturation or damage at temperatures above 
60°C [21,24]. These solutions are heated in either warm water baths or incubators at 
temperatures above 60°C for about ten to eleven hours [21,24]. Although this process 
runs for many hours, after only ten minutes most viruses are inactivated [21]. At the end 
of pasteurization, the stabilizers are removed by means of filtration, precipitation, or 
chromatography [24]. Afterwards, tests are conducted to ensure the proteins were not 
damaged and recovered from heat exposure, and that no viruses remain in the solution 
[21]. A downside to this viral reduction method is that it may reduce the biological 
activity of the proteins within the solution by up to 30% [24]. Currently, commercially 
developed fibrinogen sealants, composed of fibrinogen and thrombin, complete virus 
reduction using pasteurization at a temperature of 60°C for about ten hours [25].  
2.10.2.2 Dry Heat 
Dry heat is implemented at the final stage of processing and requires an oven with 
guaranteed homogenous exposure to temperatures ranging from 60°C to 100°C. The 
product must be exposed to these temperatures for anywhere between a few minutes and 
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a few days, depending on the viruses’ characteristics, concentrations, and reduction 
resistance [24]. Fibrinogen and thrombin-based products are typically exposed to dry heat 
for about thirty minutes for virus reduction to occur [25]. Similar to that of pasteurization, 
the dry heat treatment also requires the usage of stabilizers [24]. This method is often 
deemed less effective than pasteurization, but alternatively it does not need to be applied 
to the liquid state, rather the final product [24]. Therefore, this method should be used as 
a secondary virus reduction method to ensure the reduction of more resistant non-
enveloped viruses [24].  
2.10.2.3 Vapor Heat 
Vapor heating must occur when the product is in the dry form in order to be 
effective [24]. By adding water vapor to the product before heating, increased level of 
viral inactivation can be achieved [21]. This results in an environment with high moisture 
levels and no oxygen, that is steam-like [24]. Viral inactivation occurs over ten hours, 
when vapor pressures are between 1190-1375 mbar and the temperature remains between 
60°C and 80°C [24]. Currently, commercial products are implementing steam treatment 
on fibrinogen and thrombin by exposing the dry components to steam at 60°C for 
approximately thirty hours [25].  
2.10.2.4 Precipitation 
 Precipitation purification is a reduction method that is effective on both enveloped 
and non-enveloped viruses. This process is the fractionalization of the virus into solid and 
liquid components. Ethanol precipitation is the most prevalent form implemented 
worldwide [21]. Ethanol functions not only as a precipitant, but also a disinfectant. 
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However, this is typically only effective at room temperature and the precipitation 
process must occur at low temperatures [21].  
In precipitation, components are separated during the transition between the solid 
and liquid phases. Once precipitated, the proteins undergo centrifugation to combine 
together the viral material. From this point, the viral bulk is removed through filtering 
[21]. This precipitation method must be coupled with other reduction technique to meet 
FDA standards.  
The major drawback of this method is the consistency. It has proved difficult to 
expose each fractional component to the same amount of precipitate. The proof of viral 
reduction by precipitation is easy to obtain in small-scale productions, but is difficult to 
consistently prove in a large scale system [21]. This method has proven to be a great 
method used in the production of plasma based products, such as intravenous and 
intramuscular immunoglobulins [21]. Overall, precipitation is primarily dependent on the 
protein composition and the separation environment, which does not always prove easy 
to validate [21].  
2.10.3 Chromatography  
Similar to precipitation, chromatography is dependent on the protein composition 
and separation conditions [21]. The protein purification process of chromatography can 
remove both enveloped and non-enveloped viruses. Chromatography columns are loaded 
with an internal resin, which absorbs the protein or virus of interest. The column resin, 
the protein solution, and the buffer influence viral reduction. A drawback of this process 
is the inconsistency between viruses. Resins are virus-specific and will not remove all 
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possible contaminants. The quality of the resin may also affect the ability to purify the 
biological samples [21]. 
In ion exchange chromatography there is typically a 2-3-log reduction factor. In 
specific chromatography processes, such as affinity chromatography, up to a 5 log 
reduction has been verified [21]. There are a number of factors to consider when using 
this method:  
• Column geometry 
• Composition and flow rate of the buffers  
• Intermediate wash steps  
• Protein composition  
• Preparation of the chromatography resin 
 
In a study using ion exchange chromatography, albumin and IgG were purified of 
a few bovine related viruses, including Bovine Herpesvirus and Bovine Viral Diarrhea. 
The results showed more than 6.4 log reduction after the reduction. This method was run 
in combination with other clearance methods to optimize the viral reduction [26]. 
2.11 Viral Reduction Factor Testing Methods 
As described in the statistics section (4.2.1) of the literature review, the viral 
reduction factor is indicative of the reduction system’s effectiveness. A testing method 
must be employed in order to estimate the remaining viral concentration after the 
clearance process. Based on this value, the viral reduction factor can be calculated. The 
main testing methods examined here involve microscopy, plaque assays, quantitative 
polymerase chain reaction (qPCR) and outsourcing.  
2.11.1 Microscopy 
Using electron or fluorescent microscopy is a precise method to estimate 
remaining viral concentration. The Fluorescent Focus Assay (FFA) is a technique that 
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utilizes antibody staining for viral detection. Specific antibodies with fluorescent tags will 
bind to viral antigens. The number of tags seen under the microscope represents the 
amount of remaining virus for a given sample area. This method is considered more 
sensitive than many others, but ultimately more difficult and expensive. Many of the tags 
needed to detect viruses are not commercially available and if available are expensive 
[27].  
Transmission electron microscopy (TEM) approach is another method for viral 
detection. TEM was one of the first detection techniques used for viral diagnosis, with a 
detection limit of 105 particles/mL. However, by the 1990s, other techniques were 
invented and were proven superior. TEM is advantageous for observing molecular 
characteristics, such as morphology or new viral classifications. Yet, this technique may 
require years of experience to distinguish viruses and cannot detect a large sample batch. 
Furthermore, this method was mostly replaced with assays that are cheaper, user-
friendlier, and can assess larger quantities [28].  
2.11.2 Common Industry Tests 
TEM has been generally replaced with assays such as qPCR, enzyme-linked 
immunosorbent assay (ELISA), and hemagglutination assay (HA). The qPCR technique 
detects specific genetic base pairs on the viral genome. It does this through the use of 
fluorescent tags that binds to the genome, or a primer that contains a tag. As the genetic 
material becomes amplified, the tags are tested using cytometry. Their prevalence 
represents the amount of viral genetic material in the sample and is therefore, 
proportional to the amount of virus present. This method is highly reproducible, relatively 
time efficient, and involves moderate prep work. The main drawback is its cost through 
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purchasing the required tags, primers, and PCR kits. ELISA is another highly sensitive 
technique and uses antibodies for viral protein detection. The viral protein is extracted 
from the sample. An antibody will attach to the viral protein (antigen) that is also 
attached to an enzyme. A substrate is introduced and the activity of the enzyme is 
translatable to the concentration of virus. It is very sensitive, with a minimum detection 
range of 1012 - 109 moles/L depending on the type of ELISA used. The HA test is an 
indirect way to test viral concentrations. It is based on the principle that specific viruses 
express the hemagglutinin protein on their surfaces and will form agglutinates with red 
blood cells. The amount of agglutinate, or clumps of red blood cells, that forms as a result 
of a known concentration of red blood cells can estimate viral concentration. The 
drawbacks include tediousness of sample preparation, and maintenance of fresh red blood 
cells [27].  
2.11.3 Plaque Assay and Bacteriophages 
 Plaque assays can be used to test viral concentrations. There are many drawbacks 
when applying this method with mammalian viruses and it is often more useful when 
working with bacteriophages (viruses that kill bacteria). The assay works by spreading 
bacteriophages over a cultured lawn of bacteria. The bacteriophages infect and lyse the 
bacteria, leaving spotted areas indicating bacterial death. These areas, or plaques, 
represent the titer of bacteriophage that was in the initial concentration spread over the 
cultured plate. This method is less expensive than most common industry procedures, but 
is only available if bacteriophages are used for viral reduction testing.  .
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2.11.4 Other Non-Traditional Methods and Outsourcing 
The procedures described above are the most commonly used for calculating the 
remaining virus in a sample. Although not commonly used, flow cytometry is a method 
with increasing popularity in virology. It works by recording how light scatters as it 
passes through a sample. Originally, researchers did not believe they could identify a 
particle as small as a virus with this technique. In the late 1990s, researchers did detect 
viruses with flow cytometry using a nucleic acid staining dye. Brussaant et al. used the 
nuclear stain SYBR Green I and was able to detect a wide range of viral families [29]. 
Western blots have been utilized for viral protein detection as well. Viral detection via 
western blotting works through identifying, isolating, and quantifying certain proteins 
that are only expressed in the viral genome [30]. Another option, rather than in-house 
testing, would be to outsource the samples to a company that performs viral 
quantification testing. Most of these companies use the same techniques described above. 
BioReliance performs testing of bovine derived viruses based on the federal 9 CFR rules 
and regulations. This law overlaps with the FDA requirements for bovine and porcine 
products. Also, BioReliance can develop testing methods for the customer’s needs [31]. 
There are a number of other companies that will detect and quantify viral contamination. 
Outsourcing would be easier, but could be the most expensive option depending on 
several factors.  
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3.0 Design Strategy 
3.1 Initial Client Statement  
The client provided us with the following initial client statement: The fibrin 
microthread sutures developed by the Gaudette and Pins lab needs to be translated from 
pre-clinical to clinical trials. To do so, a viral reduction system would need to be 
incorporated into the manufacturing process for FDA approval.  
3.2 Design Requirements-Technical  
3.2.1 Objectives 
In this project, the main focus will be the reduction of bovine-related viruses from 
the Fibrin Microthread product. VitaSutures will need to meet FDA standards in order to 
ensure patient safety and move into clinical testing. The main objectives of the project are 
to:  
• Identify and meet relevant FDA standards for bovine virus reduction  
• Evaluate bovine virus reduction techniques 
• Develop a system to quantify viral reduction based on a reduction factor 
• Apply viral reduction techniques to various components of the manufacturing 
process  
• Asses the ability of the product to accomplish performance specifications after 
reduction 
o Test mechanical properties of the threads to ensure 70% of the properties 
are retained 
• Achieve a total viral reduction factor to meet FDA standards for bovine virus 
reduction 
 
After further research and testing, our team will present a proposed solution and give 
future recommendations to WPI faculty, students and VitaThreads.  
3.2.2 Functions & Specifications  
In order for this viral reduction process to be developed, certain functions and 
specifications will be implemented. This project must be completed in a 25-26 week time 
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span, which encompasses the amount of time allotted for a Major Qualifying Project. A 
virus reduction process must be developed within the $750 budget and kept under an 
additional $10 cost added to each suture for the consumer market. A fibrin microthread 
suture with a viral reduction factor must be achieved for each step and ideally a viral 
reduction factor of 12 for the entire system, while still maintaining 70% of its original 
mechanical properties. In order to ensure the desired viral reduction factor, an accurate 
assay with a p-value less than 0.05 will need to be implemented.  
3.2.3 Constraints  
 The constraints given by this project are broken up into lower and upper bound 
categories. The lower bound category is defined by the minimal constraints that need to 
be met. Constraints in the upper bound group must be met and cannot be compromised. 
In the lower bound category, the viral reduction must minimally meet the FDA 
requirements for viral reduction in the entire process. The purified threads must obtain at 
least 70% of the original mechanical properties. This threshold, provided by Gaudette and 
Pins labs, was based on the minimum required ultimate tensile strength to maintain 
functionality in clinical applications. In relation to the product, the fibrin microthreads 
must form after virus reduction. In the upper bound constraints, there is a limited budget 
of $750 supplied to the team through the institution. Given the limited budget, there is 
also a constrained amount of supplies and product available. Time is a very large 
constraint in this category with a time frame of 25-26 weeks.  
3.3 Design Requirements-Standards 
 As described in the literature review, the FDA issues standards for viral clearance 
systems. These standards must be met in order for the FDA to approve the product for 
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human clinical trials. The FDA’s three principle approaches for evaluating viral reduction 
systems is as follows: 
1. Analyzing viruses tested and how they encompass all other potential viral 
contaminants. 
2. Assessing the capacity of the production process to clear viruses, based on 
reduction factor calculations. 
3. Testing the product at appropriate steps for viruses. 
 
This project mainly focuses on standards 1 and 2. Standard 3 is specific to the 
full-scale production process. Within standards 1 and 2, the FDA provides more 
information as to how they judge the effectiveness of the clearance system, as described 
below: 
• Appropriateness and selectivity of test viruses 
• Design of the testing study 
• Amount of viral reduction achieved 
• Time dependence 
• Effects of variations in process parameters 
• Limitations of different reduction and testing methods 
 
Within the “appropriateness and selectivity of test viruses,” the FDA looks for three 
different classes of viruses to test, that both encompass enveloped and non-enveloped 
characteristics. These classes are: 
• Relevant: the same virus or within the same species 
• Model specific: closely related, within the same genus/family 
• Model non-specific: no particular viruses, indicative of randomness of viral 
contamination in nature 
 
Moreover, the second FDA standard encompasses the viral reduction factor. A reduction 
factor over 4 for one step is considered effective. All together, the total reduction of the 
clearance system must reach at least 12 [34]. The study must achieve a 95% confidence 
interval. Lastly, the FDA will look specifically at limitations in the system. These 
include, but are not limited to: 
. 24.
• Viral resistance 
• Summation of reduction steps when calculating reduction factor may overestimate 
potential of system. 
• Steps that too closely resemble one another in reduction technique. Identical 
procedures cannot be counted twice in reduction factor unless justified. 
• Scaled-down process may not accurately reflect full scale.  
 
In all, these FDA standards must be met in order to establish an effective viral reduction 
system and move towards human clinical trials. 
3.4 Revised Client Statement 
From the Gaudette and Pins labs, it was determined that there was a need to 
complete viral reduction in the fibrin microthread sutures. Viral reduction is an essential 
step to obtain FDA approval for translating research into clinical trials. Therefore, it was 
necessary to develop and design a process to overcome this challenge. The process must 
meet FDA standards, while maintaining at least 70% of the suture mechanical properties. 
Additionally, a method must be developed to test both the soluble and fibrin thread to 
quantify viral reduction.  
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4.0 Design Process 
4.1 Needs Analysis 
The project statement as a whole was further broken down into the specific needs 
and wants. The development of fibrin microthreads with a reduced virus concentration 
must be an inexpensive method that does not increase the cost per suture by $10. The 
viruses present in the fibrin microthreads must be removed while its components are in 
the powder or liquid phase, or after the suture development. This will ensure that the final 
product has reached the desired viral reduction factor of 12. In order to confirm the viral 
reduction factor, an assay with high accuracy (p<0.05) must be implemented. This assay 
can be either completed in-house or outsourced for confirmation. After the viral reduction 
procedures, it must be demonstrated that the fibrin microthreads can be fully formed and 
retain 70% of its original mechanical properties. Without thread formation and at least 
70% of the original mechanical properties, the fibrin microthreads will not function as 
effectively as a suture. All of these needs must be met in order to design a successful 
virus reduction process, but the incorporation of additional wants (Table 2) could 
improve the outcome of this project for the client. .
Table&2:&Needs&vs.&Wants&
Needs Wants 
As inexpensive as possible Less than $10 additional cost per suture 
FDA approval  Viral reduction by a reduction factor of 12 
Assay to quantify and confirm viral 
reduction factor 
Ensure the current packaging system for sutures is 
not compromised 
Maintain 70% of the original 
mechanical properties of the sutures 
Incorporation of virus reduction process into the 
manufacturing process (continuous process) 
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4.2 Conceptual Designs 
4.2.1 pH Alterations  
The first method used to treat both fibrinogen and thrombin was pH alterations. 
Changing the pH of the solution, to either acidic or basic, can be used to disrupt the lipid 
envelope of a virus for reduction [21]. The most effective solutions should be treated at a 
pH of less than 6.0 or greater than 10.0 to remove almost 90% of the present viruses [23]. 
The trials for pH testing can be seen in Table 3 below, which are in chronological order. 
All trials began with thrombin and fibrinogen dissolved in HBSS, that were treated to a 
specific pH level. Five minutes later the pH level was measured to determine if it had 
remained constant. If the pH level did not remain constant the solution pH was adjusted 
again to bring it back to the initial pH level. The solution pH was altered using 0.1 M 
NaOH for basic pH adjustments and 0.1 M HCl for acidic pH adjustments.  
Thrombin and fibrinogen were both dissolved in a 20 mM HEPES buffered saline 
solution (HBSS) for microthread manufacturing. However, since HBSS buffers the pH 
capacity of a solution, the fibrinogen and thrombin must be dissolved into saline to 
accurately test the effect of the acid/base treatment. The final product would then be 
lyophilized and reconstituted in HBSS for microthread manufacturing.  
The acid/base treatment began by altering the pH of saline to an acidic or a basic 
pH and then adding fibrinogen powder (Trials 1 & 2). Saline was utilized, in combination 
with the fibrinogen and thrombin, in order to provide enough solution for lyophilization 
and potentially allow for an easier pH alteration to avoid immediate clotting of the 
product. Within five minutes, the pH changed. Additionally, clotting was present in the 
solution and could not be brought back to their initial pH. It was then hypothesized that if 
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fibrinogen dissolved in saline were treated together, potential clotting would not occur 
(Trials 3 & 4). After bringing the pH to 4.00 or 12.00, both solutions reached an 
approximate neutral pH after 5 minutes and clotting was present. It was then 
hypothesized that if the solutions were brought past their isoelectric point (the point at 
which a molecule carries no net electrical charge) clotting could potentially be avoided. 
In trials 5, 6, 7, and 8 saline was altered to the highest basic pH (13.80) or the lowest 
acidic pH (-0.05) that could be reached. When fibrinogen was added to these solutions 
clotting occurred in the acidic treatments, although the solutions did not return back to a 
neutral pH after 5 minutes. The trials where fibrinogen was treated with base (Trials 6 
and 8) were lyophilized, but could not be redissolved in HBSS. After trials 1-8, it was 
determined that fibrinogen could not be treated with acidic or basic conditions due to 
clotting or its inability to re-dissolve. 
Next, acid/base treatment was performed on thrombin. Trials 9, 10, and 11 show 
that 0.4 ml (16 units total) of thrombin were added to 1.6 ml of saline for acidic or basic 
pH treatment. The pH of all three solutions were easily adjusted and remained constant at 
a pH of either 4.00 or 12.00. These solutions were then lyophilized, and trials 10 and 11 
were able to go back into solution using HBSS and to be used to form fibrin microthreads 
with untreated fibrinogen.  
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Table&3:&pH&Testing&Trials&
Trial Treatment&Type 
Initial&
Component(s)&
Treated 
Initial&
pH 
Component&
Added 
pH 
Post&5&
minutes 
Alteration 
Attempts 
1 Acid Saline 4.00 140.mg.Fibrinogen 6.11 pH.back.down.to.4.0 
2 Base Saline 12.00 140.mg.Fibrinogen 9.10 pH.back.up.to.12.0 
3 Acid Saline.+.140.mg.Fibrinogen 4.00 _______ 6.47 pH.back.down.to.4.0 
4 Base Saline.+.140.mg.Fibrinogen 12.00 _______ 6.36 pH.back.up.to.12.0 
5 Acid 3.ml.Saline 2.00 140.mg.Fibrinogen 4.00 _______ 
6 Base 2.ml.Saline 13.97 140.mg.Fibrinogen 13.14 Lyophilize 
7 Acid 2.ml.Saline T0.05 140.mg.Fibrinogen T0.37 Neutralize 
8 Base 2.ml.Saline 13.94 140.mg.Fibrinogen 13.89 Lyophilize 
9 Acid 1.6.ml.Saline.+.0.4.ml.Thrombin.(8.U/200.μL) 4.00 _______ 4.00 Lyophilize 
10 Base 1.6.ml.Saline.+.0.4.ml.Thrombin.(8.U/200.μL) 12.00 _______ 12.00 Lyophilize 
11 Acid 1.6.ml.Saline.+.0.4.ml.Thrombin.(8.U/200.μL) 4.00 _______ 4.00 Lyophilize 
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4.2.2 Heating Method  
The heating viral reduction method was broken down into dry and vapor heat. Dry 
heat is a method that should be applied to the final product and must be treated in a 
homogeneous environment. This method should be used as a secondary virus reduction 
method, to ensure the reduction of the more stable non-enveloped viruses [24]. Vapor 
heating should be used on the powder product in order to be effective [24]. When the 
product is exposed to water vapor before heating in an incubator-like system, it may lead 
to increased viral inactivation [21]. Methods are as follows: 
4.2.2.1 Dry Heat 
 The first heat treatment method encompassed a dry heat step applied to the final 
microthread product. Dry heat eliminates humidity. In this experiment, threads were 
placed into an oven at varying temperatures for thirty minutes. Four trials were run, each 
with a sample size of five threads. The dry heat trials can be seen in Table 4. After heat 
treatment, all threads were mechanically tested using an Instron. 
Table&4:&Dry&Heat&Trials&
Trial Specifications 
1 5 threads at 60°C for 30 minutes  
2 5 threads at 80°C for 30 minutes  
3 5 threads at 100°C for 30 minutes  
4 5 threads not exposed to heat treatment (Control Threads) 
4.2.2.2 Vapor Heat 
The second treatment tested was vapor heating of the fibrinogen powder. In the 
first component of the vapor heat testing, fibrinogen powder was exposed to water vapor 
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at 60°C for thirty hours. This is done prior to the dissolution of the fibrinogen. The next 
vapor heat experiment executed incorporated both vapor and dry heat, in which 
fibrinogen powder was first treated with vapor heated for thirty hours at 60°C. The 
powder was then immediately dry heated for an hour at 60°C. The control for these 
experiments was untreated fibrinogen powder. Threads were made with untreated 
thrombin and were all mechanically tested using an Instron.  
4.2.3 Solvent Detergent and Protein Precipitation  
 Triton-X100 and TNBP are commonly used solvent detergents that can be utilized 
as a viral reduction method. Ammonium sulfate and ethanol have both been widely used 
for protein precipitation [37]. A combination of the solvent detergents and precipitation 
methods allow for this viral reduction technique to be incorporated into the viral 
reduction system. This protocol was derived from the Purification of Fibrinogen from 
Human Plasma by Ayman Ismael and supplemented with the needed alterations [39]. 
     The fibrinogen powder was dissolved in HBSS to a final concentration of 
70mg/mL. To begin, TNBP and Triton-X100 were added to the fibrinogen solution to a 
final concentration of 0.15% and 0.5%, respectively, with continuous stirring overnight. 
This was also tested at 2X and 5X concentrations of TNBP and Triton-X. The following 
day, a 4 M ammonium sulfate solution was made and chilled on ice. The solvent 
detergent treated fibrinogen solution was chilled on ice and then altered to a 1 M 
ammonium sulfate solution utilizing the 4 M ammonium sulfate solution. The treated 
fibrinogen solution immediately precipitated and was and stored on ice overnight to 
continue the precipitation. The next day, the fibrinogen solution was centrifuged at  4000 
x g for 20 minutes. Upon completion, supernatant was removed and the remaining 
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protein was resuspended in an amount of HBSS equivalent to the amount of starting 
fibrinogen solution. The solution was treated with a second 1 M ammonium sulfate 
treatment and was chilled overnight for a second time. On the following day, the conical 
tube containing the fibrinogen product was once again centrifuged at 4000 x g for 20 
minutes. The supernatant was then removed and resuspended in the same amount of 
HBSS as before. The tube containing the precipitated fibrinogen and HBSS was then 
vortexed and warmed in a water bath to obtain homogeneity and to solubilize the 
precipitated fibrinogen. Once achieved, threads were made with untreated thrombin and 
the final product was mechanically tested. 
The protein purification process using the ammonium sulfate was repeated using 
ethanol as a substitute for the ammonium sulfate. To begin, 0.15% microliters of TNBP 
and 0.5% of Triton-X100 were added to the fibrinogen. Solution was stirred for 
approximately forty minutes. 10% ethanol was added and chilled at -4°C overnight. 
 4.2.4 Pasteurization 
Both fibrinogen and thrombin were heated in their liquid states. There was no 
noticeable disruption in thrombin, but fibrinogen clotted when heated to 60°C or higher. 
Stabilizers were used to restrict clotting based on the literature. Literature demonstrated a 
reduction in clotted fibrinogen exposed to heat at 60°C or higher by using a sugar, amino 
acid, and magnesium salt cocktail [38]. As shown in Table 6, Trials 1-3 tested sucrose, 
serine, and magnesium chloride in ranges of 80-100% w/v, 7.5-10% w/v, and 50-100 
mM, respectively. Trials 4-6 used xylitol instead of sucrose and glycine instead of serine. 
In trials 1-6, the concentration of fibrinogen was 70mg/ml, or 7% w/v. It was thought that 
this concentration was slightly high based on the paper’s recommendations for a 0.5-6% 
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w/v fibrinogen [38]. Thus, 70 mg of fibrinogen was dissolved in at least 2 mL of HEPES 
or DI water, and trials were repeated with xylitol, serine, and magnesium chloride. All 
samples were placed in the incubator at 60°C for at least an hour. If there was any visible 
clotting, the samples were vortexed to see if the fibrinogen would dissolve back into 
solution.  
4.2.5 Mechanical Testing  
 Mechanical testing was performed on threads made after their respective 
reduction technique. Threads were glued 30 mm apart on their corresponding ends to a 
piece of velum paper. The glued threads were hydrated in PBS for approximately 20 
minutes, imaged, and the diameter measured using ImageJ; 5 measurements were taken at 
each end of the thread and then averaged. Threads were attached on each end to a tensile 
tester (Instron) that slowly pulled them apart at a strain rate of 10mm/min until failure 
occurred. Data was acquired using an Instron for tensile strength and strain, which was 
then used to calculate the elastic modulus and ultimate tensile strength (UTS). The UTS 
was the maximum stress before the thread ruptured and the elastic modulus was this 
stress divided by the respective strain. Results were compared across all threads to see 
which reduction methods maintained at least 70% of thread performance specifications in 
relation to the non-treated control. These results were used to propose, verify and select a 
final design. 
4.2.6. Plaque Assay  
Plaque assays were used to estimate bacteriophage titer after various stages in the 
reduction process. In this method, bacteriophages will infect and lyse bacteria leaving an 
area of no growth, referred to as a plaque. A relationship between number of plaques and 
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bacteriophage concentration can then be developed. The needed materials were 
purchased from Carolina Biological, which included the basic bacteriophage culture set B 
(item #121160), plaque assay plating set (item #124730), and additional bacteriophages 
(item #124425 and #124335). Upon arrival, the bacteriophages and bacterial cultures 
were kept at 4°C until use.  
To validate this assay, plates were prepared by autoclaving the tryptone soft agar 
provided in the plaque assay plating set for 15 minutes at 121°C. The hot agar was 
allowed to cool to 50-60°C and then poured into the plates and allowed to solidify before 
being inverted and transferred to 4°C for storage. The E. Coli was in a hardened slant 
culture and a swab of bacteria was taken from the slant culture and inoculated in LB agar 
6 hours prior to conducting the plaque assay. After this time, bacteria concentration was 
normalized to 108 CFU/ml based on the 1.0 McFarland Standard and 100 µL of bacteria 
was plated in each trial. The first plaque assay used 1 mL of top agar in combination with 
the following amounts in Table 5. This was repeated without trial 4 during the next 
plaque assay run. The plates were placed at 37°C for 24 hours to allow plaques to 
develop.  
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Table&5:&Components&of&Plaque&Assay&Trials&
Trial Viral Parts Viral Concentration* Bacteria MgCl2 (10mM) 
1 10^8 890 µL A 100 µL 10 µL of 1M solution 
2 10^6 890 µL B 100 µL 10 µL of 1M solution 
3 10^4 890 µL C 100 µL 10 µL of 1M solution 
4 10^2 890 µL D 100 µL 10 µL of 1M solution 
5 (negative control) 0 890 µL only PBS 100 µL 10 µL of 1M solution 
*Viral Concentration in serial dilutions: 
A: 10 µL viral stock + 990 µL PBS 
B: 10 µL A + 990 µL PBS 
C: 10 µL B + 990 µL PBS 
D: 10 µL C + 990 µL PBS 
 
 As no plaques formed, it was determined that the top agar inhibited plaque 
formation and was not used for the third and fourth attempts. For the third attempt, the 
solutions in Table 5 were spread with a swab over the bacterial culture plate. In the fourth 
attempt, a zone of inhibition procedure was conducted using small paper discs with a 
diameter of 6 mm. The discs were suspended in the solutions from Table 5 for 1 hour and 
placed on the agar plates with already applied E. Coli. The plates were incubated at 37°C 
for 24 hours and images of the plates were taken and were analyzed using ImageJ to 
determine diameter. From the changes in diameter, a curve was constructed that related 
the diameter formed to the bacteriophage titer.  
 This assay was also used for the final dry heat reduction step. The threads were 
degraded in a 0.5mL solution consisting of 20µL of 0.3 plasmin and 480µL PBS at 37°C 
overnight. The paper discs were then loaded and the test was performed identically to 
what was previously described.  
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4.3 Alternative Designs 
 FDA standards for viral reduction in bovine-derived products require two viral 
reduction techniques to be applied. Five different techniques were considered for viral 
reduction in both fibrinogen and thrombin: pH treatment, pasteurization, precipitation, 
dry heat and vapor heat. A combination of two to four of these methods were used for the 
final design, dependent on their viral reduction factors and their ease of implementation 
during the manufacturing process. Although the main goal was to have two methods that 
can be applied to both fibrinogen and thrombin, it was necessary to have separate 
methods for each component to achieve the highest possible viral reduction factor. All of 
these methods were tested to determine if threads were able to form and maintain 70% of 
their original mechanical properties. The viral reduction methods: dry heat, vapor heat, 
pasteurization, pH treatment methods, nanofiltration, and solvent detergent were all 
tested and applied to both thrombin and fibrinogen at their different states. After all of the 
methods were evaluated based on cost, thread formation, and thread mechanics the final 
design was determined.  
4.4 Final Design Selection  
A final design system that includes three potential methods was deemed efficient 
in viral reduction, as well as 70% retainment of the original mechanical properties. 
Solvent detergent can be applied to fibrinogen in the liquid state, while acid pH (4.00) 
treatment can be applied to thrombin. Once the fibrinogen and thrombin were treated, as 
described in the methods above, the liquid solutions were coextruded to make the final 
product, fibrin microthreads. After the fibrin microthreads were formed, the dry heat 
treatment method was be applied for 30 minutes at 60°C. The FDA recognizes 
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ammonium sulfate precipitation and pH alteration as primary reduction methods, while 
dry heat can only be implemented as a secondary method of viral reduction. Figure 1 
outlines the process for the treatments for viral reduction, as well as our quantification 
system to measure viral reduction.  
 
Figure&1:&Final&Design&Process&and&Testing 
5.0 Design Verification 
5.1 pH Alteration Results 
After completing the 11 trials mentioned in Section 4.2.1, only trials 10 and 11 
were able to return the base products to a solution after pH treatment and lyophilization 
that could be used to create microthreads. Trials 1-9 either experienced clotting, could not 
be lypophilized, or failed to return to solution after lyophilization. The solutions needed 
to be lyophilized and then resuspended to regain the proper concentration to make 
threads. Trial 10 was base treated saline and thrombin and trial 11 was acid treated saline 
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and thrombin. Once resuspended in solution after lyophilization, these solutions were 
used separately to make fibrin microthreads. 
The basic pH treated thrombin (trial 10) was used with untreated fibrinogen to 
make fibrin microthreads. When the threads were drawn out into the HEPES filled pan 
threads could be visually seen. However, the threads were completely adhered to the pan 
and could not be removed. The base pH treated threads could not be removed from the 
pan potentially due to the property changes of thrombin, which may have arose during 
pH treatment. A second attempt was made to create the threads from the same solution, 
but the same end result occurred. Therefore, we determined that the basic pH treatment of 
thrombin does not allow for thread properties to be maintained. The only successful trial 
from this study was the acid pH treated thrombin. This mixture could be lyophilized and 
brought back into solution and used to make threads with untreated fibrinogen. The 
threads formed as expected and the threads were easily removed and dried. After 24 
hours of drying, the threads were removed from the drying rack and sections of the 
threads were used for mechanical testing. Based on these results, it was determined that 
the thrombin in solution with 850µL of 5 M CaCl2 could be treated to a pH of 4.0 and 
then lyophilized. After lyophilization, the product was resuspended in 850µL of HBSS 
and 850µL of 5 M CaCl2. This allowed for threads to be formed as normally expected. 
Thread properties were determined using mechanical tests. The results obtained from the 
mechanical testing, can be seen in section 5.6. 
 5.2 Dry Heat Results  
The dry heat method applied to fibrin microthreads at varying temperatures did 
not visibly indicate any change to the threads. The threads did not appear to exhibit any 
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deformation or degradation. Mechanical properties were tested and results can be viewed 
in Section 5.6..
 5.3 Vapor Heat Results  
 Fibrinogen was treated with vapor heat, for 30 hours at 60°C, during the treatment 
the fibrinogen absorbed water. After treatment, the fibrinogen weighed approximately 
two-fold more than the original product and could not be dissolved in the HEPES buffer 
solution. Next, fibrinogen was treated with vapor heat for 30 hours with an additional dry 
heat step to remove the absorbed water. Similar to vapor heat alone, the fibrinogen was 
unable to dissolve into the HEPES buffer. As the fibrinogen could not be dissolved, the 
thread formation step was not performed utilizing this treatment method..
 5.4 Solvent Detergent with Precipitation Results 
The solvent detergent method was successfully applied to fibrinogen, when used 
in combination with ammonium sulfate precipitation. After the second overnight chilling, 
the fibrinogen was centrifuged for a second time and resuspended in HBSS. After 
approximately thirty minutes of vortexing and warming in the water bath the fibrinogen 
was able to fully dissolve in HBSS. The remaining product was used to make threads 
with untreated thrombin. Fibrin microthreads were successfully formed when using the 
normal and 2X (0.3% TNBP and 1.0% TritonX-100), solvent detergent treated 
fibrinogen. However, the 5X (0.45% TNBP and 2.5% TritonX-100) solvent detergent 
treated fibrinogen and untreated thrombin did not allow for thread formation. Refer to 
Section 5.6 for a detailed explanation of the mechanical properties of threads formed after 
protein precipitation.  
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The solvent detergent method in combination with ethanol precipitation was 
unsuccessful. The fibrinogen and ethanol solution was stirred for forty minutes and the 
solution became cloudy (Figure 2). The flask was chilled overnight and the next day it 
was found that the contents had formed into a gel. The gel did not go into solution and 
threads could not be manufactured from this trial. .
........ ....... .
Figure&2:&Ethanol&Precipitation&Flask&
5.5 Pasteurization Results 
As described in Table 6, trials 4-6 yielded an excessive amount of clotted 
fibrinogen, which prohibited thread making. Table 7 shows the trials with diluted 
fibrinogen concentrations (3.5% w/v or lower). Trial 9 had minimal clotting and was 
passed through a 27G needle to remove solids and make threads. The threads did not 
form in the pan, most likely due to a dilute concentration of fibrinogen. Pasteurization 
was deemed an unsuccessful method for treating fibrinogen for viral reduction. 
&........
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Table&6:&Pasteurization&Trials&
Trial Sucrose (% w/v) 
Serine 
(% w/v) 
MgCl2 
(mM) Result 
1 80 7.5 50 Clotted 
2 100 10 100 Clotted 
3 80 7.5 50 + 90mM CaCl2 Clotted 
 Xylitol (% w/v) Glycine (% w/v) MgCl2 (mM) Result 
4 80 7.5 50 Partial clot 
5 100 10 100 Partial clot 
6 80 7.5 50 + 90mM CaCl2 Partial clot 
&
Table&7:&Further&Pasteurization&Testing&
Trial Specifications Result 
7 Repeat trial 4, but with 3.5% w/v fibrinogen Partial clot - no noticeable difference 
8 
Repeat trial 4, but dissolve xylitol in 
water prior to adding with other 
stabilizers and fibrinogen 
Clotted 
9 Repeat trial 5, but with 70mg/3ml fibrinogen 
Smallest clot out of all trials. Was 
filtered using 27G needle. Threads did 
not form most likely from lack of 
fibrinogen concentration. 
10 
Repeat trial 9 to increase fibrinogen 
concentration. 140mg/3ml 
fibrinogen 
Clotted 
5.6 Mechanical Testing 
 As described previously, fibrin microthreads underwent mechanical testing after 
their respective viral reduction technique in the absence of viruses. For initial mechanical 
testing, tested groups were either treated thrombin or treated fibrinogen, but not the 
combination treatment. This procedure was implemented to determine which methods 
would most effectively maintain at least 70% of their mechanical properties, analogous 
with the revised client statement. Additionally, these data informed which treatments 
would be used going forward to test threads made from treated fibrinogen and thrombin. 
Tensile strength was tested, because that is the most important mechanical property of the 
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threads in order to ensure efficiency in clinical applications. Elastic modulus was 
calculated by dividing ultimate tensile strength (UTS) by strain at the UTS. See Appendix 
B for the stress/strain curves of each reduction technique. The results were demonstrated 
that all groups maintained at least 70% of the original mechanical properties in relation to 
the control threads. The UTS and elastic modulus were variable and not all groups 
maintained 70% UTS and/or modulus. Figures 3, 4, and 5 compare strain, UTS, and 
modulus, respectively. The bars represent mean and the error bars are standard deviation. 
Table 8 displays which techniques were tested to determine their UTS, strain, and 
modulus in relation to the original control values. For each method, 6-8 threads were used 
for mechanical testing.  .
.
Figure&3:&Percent&Strain&for&Each&Tested&Viral&Reduction&Method&.
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.
Figure&4:&UTS&Measurements&for&Each&Tested&Viral&Reduction&Method&.
.
Figure&5:&Elastic&Modulus&Measurements&for&Each&Tested&Viral&Reduction&Method&.
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Table&8:&Comparison&of&UTS,&Strain,&and&Elastic&Modulus&Values&for&Tested&Viral&Reduction&Methods&
& UTS& Strain& Elastic&Modulus&
Fibrinogen&Dry&
Heat&
No.–.62%. Yes. No.–.63%.
Fibrinogen&
Protein&
Precipitation&
No.–.53%. Yes. No.–.42%.
Thread&Dry&Heat&
60°C&
No.–.25%. Yes. Yes.
Thread&Dry&Heat&
80°C&
Yes. Yes. Yes.
Thread&Dry&Heat&
100°C&
Yes. Yes. Yes..
Pasteurized&
Thrombin&
No.–.32%. Yes. No.–.49%.
Thrombin&with&
pH&of&4&
No.–.53%. Yes. No.–.53%.
  
The two methods with 70% or more retainment of the original mechanical 
properties of the fibrin microthreads ere dry heating at 80°C and 100°C. This would only 
count for one step in the reduction processing according to the FDA. Therefore, using 
these data it was determined that acid treated thrombin and precipitated fibrinogen 
yielded the best results and were retested. For the retest, all threads were made on the 
same day and made by the same person to further control additional variables. Figures 6, 
7, and 8 show the mechanical testing results for the retest, where bars are the mean and 
error bars are standard deviation. The treated (no heat) group refers to only the fibrinogen 
protein precipitation and acid thrombin, while the treated (with heat group) includes the 
former with dry heat, for 30 minutes at 60°C. The red line across each graph refers to 
70% of the control.  
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.
Figure&6:&UTS&of&Threads&after&Fibrinogen&Protein&Precipitation/Acid&Thrombin,&and&after&Dry&Heat&.
.
Figure&7:&Strain&of&Threads&after&Fibrinogen&Protein&Precipitation/Acid&Thrombin,&and&after&Dry&Heat&.
.
Figure&8:&Elastic&Modulus&of&Threads&after&Fibrinogen&Protein&Precipitation/Acid&Thrombin,&and&after&
Dry&Heat&
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Fibrin microthreads made from treated fibrinogen and thrombin and subsequently 
heat-treated maintained UTS and modulus values that were at least 70% of the controls. 
Confirming that the mechanics of treated microthreads were comparable to the control, 
the next step was to test these methods for a viral reduction using fibrinogen and 
thrombin spiked with bacteriophages. 
5.7 Plaque Assay Validation Results . A plaque assay was run according to Carolina Biologics protocol using a top agar 
solution and a Φx174 phage with E.Coli. This solution contained magnesium chloride for 
phage attachment, varying bacteriophage concentrations diluted in PBS, 106 CFU of E. 
Coli, and a top agar provided by Carolina Biologics. The top agar solidified before it was 
plated, so a warming plate was used to liquefy the solution to allow it to be poured onto 
the base agar. Results from this initial experiment demonstrated that no plaques were 
formed. However, since no bacteria formed on the control it was hypothesized that 
rewarming the top agar killed the E.Coli (Figure 9).  
.
Figure&9:&Plaque&Assay&Trial&1_The left picture displays the 108 titer plate with bacteria and the right is the 
positive control with only bacteria. 
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 In a subsequent attempt, the top agar was maintained in a 500C bath and quickly 
plated to avoid boiling and killing the bacteria. Three different concentrations of phages 
were used: 108, 106, and 104. In this trial, the positive control formed a lawn of E. Coli. 
The 108 and 106 plates showed almost no bacterial growth, but 104 showed little bacterial 
growth with large plaques (Figure 10). This data indicates that the high concentration of 
bacteriophage was spreading and killing the bacteria and lower concentrations of phage 
need to be used to visualize plaques. 
 
 As the top agar demonstrated difficulty in forming plaques, an assay was 
conducted without top agar using the cotton swab method. Plaques were produced in the 
104 and 102 titers, but were difficult to quantify (Figure 11). No plaque formation 
occurred in the 108 and 106 titers, but it is hypothesized that these concentration were too 
high and kill all bacteria present. To develop a relationship between plaque number and 
bacteriophage concentration, at least three plates were used to construct a curve, however 
only two plates produced plaques and the 104 could not be accurately quantified.  
Figure 10: Plaque Assay Trial 2- The left picture is 108, the center picture is 104, and the right 
is only bacteria. 
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.
Figure&11:&Plaque&Assay&Trial&3_&The&left&is&104&titer&and&the&right&is&102&titer. 
 
 To further optimize the assay, a zone of inhibition assay was performed as 
described in the methods section. Briefly 6 mm paper disks were soaked in the respective 
phage solution for 1 hour and were placed on an agar plate with a lawn of E. Coli. As the 
phage diffuses from the paper it will kill the bacteria forming laques around the paper 
(Figure 12). Greater concentrations of bacteriophage produced larger dead zones (zone of 
inhibition diameters) around the paper discs. 
 
Figure 12: Plaque Assay Zone of Inhibition Trial 4- The top left and right are 108 and 106 titers, respectively; the 
bottom left and right are the 104 and 102 titers, respectively. .
These results were quantified to produce a correlation between magnitude of 
bacteriophage titer and the average diameter of the zone of inhibition trials (Figure 13). 
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The exponential curve created was used in the following tests to quantify bacteriophage 
titer remaining after treating the fibrinogen and thrombin products. The minimum 
detectable limit was 102 titer of bacteriophage. 
 
.
Figure&13:&Relationship&Between&Plaque&Diameter&and&Titer&
5.8 Viral Reduction Results 
 The zone of inhibition plaque assay was applied to quantify a viral reduction 
factor for each step in the design. For the acid pH treated thrombin and solvent detergent 
treated fibrinogen, samples were spiked with 108 particles of bacteriophage and run on 
the plaque assay after their respective reduction step. In the final dry heat method, 
bacteriophages were loaded at a titer of 108 in the fibrinogen and thrombin, prior to 
making threads. It was anticipated that some bacteriophage would be lost when extruding 
threads. To compensate, the plaque assay was run comparing spiked threads with and 
without dry heat. Figure 14, 15, and 16 show plaque assays for final acid thrombin, 
solvent detergent fibrinogen, and dry heat treatments, respectively. 
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.
Figure 14: Acid Thrombin Reduction Step 
 
 
Figure 15: Solvent Detergent Fibrinogen Reduction Step: 2X Normal Concentration .
 
Figure 16: Comparison of loaded/dry heated threads (top two discs) and loaded/non-dry heated threads (bottom 
two discs) 
Based on these results, the zone of inhibition diameters were measured and used 
to calculate subsequent viral concentrations. Twice as much starting material was used in 
the solvent detergent method to allow for greater viral reduction. Figure 17 compares the 
normal, 2-fold increase, and 5-fold increase of Triton-X and TNBP for solvent detergent. 
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Additionally, the assay reached its minimum detectable limit of 102 bacteriophages in 
thrombin and the dry heat steps. Therefore, the reduction factor was expressed as greater 
than the reduction value. Table 9 shows these results.  
 
Figure 17: Solvent Detergent Reduction Results. Normal SD (left), 2x SD (middle), 5x SD (right) .
Table&9:&Viral&Reduction&Results&
Reduction Step Diameter (mm) Reduction Factor FDA Effectiveness 
Acid treated 
thrombin 
0 – reached minimum 
detectable limit Reduction > 6 Highly effective 
Solvent detergent 
treated fibrinogen 8.93 ± 0.91 Reduction = 3.6 Moderately effective 
Dry heat treated 
fibrin threads 
Without dry heat: 
8.58 ± 0.41 Reduction > 2 Moderately effective 
6.0 Final Design and Validation&
6.1 Final Design 
After evaluating the different outcomes, such as thread formation, cost, and thread 
mechanics, the final viral reduction system was determined. The final viral reduction 
process includes three necessary steps to ensure the desired viral reduction within the 
final fibrin microthread product. When the fibrinogen and thrombin products were 
dissolved in HBSS and reach their liquid form, the primary viral reduction steps can be 
implemented. The thrombin was treated using pH alteration by adding HCl to allow for 
the pH to reach 4.00. The fibrinogen was treated using a solvent detergent method that 
. 51.
includes the usage of Triton-X and TNBP, as well as the incorporation of ammonium 
sulfate procedures for precipitation of the solvent detergents from the final product after 
treatment. Once the fibrinogen and thrombin were treated they were co-extruded to form 
the fibrin microthreads. The fully formed fibrin microthreads were treated using terminal 
dry heat for thirty minutes as a final viral reduction step. A combination of all three of 
these processes allowed for the best viral reduction to occur in the fibrin microthread 
manufacturing process (Figure 18), in order for the threads to meet FDA standards and 
gain eventual FDA approval.  
    
Figure 18: Integration of final viral reduction system into the existing manufacturing process 
 The final design will ideally be integrated into the manufacturing process in the 
future. There is a strong belief that fibrin microthread sutures will be used universally 
throughout the healthcare field. The implications that this product will have on the 
economy, environment, society, politics, ethics, health, safety, manufacturing, and 
sustainability will need to be considered. 
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6.2 Economics 
There are economic factors that must be considered for the eventual 
implementation of the viral reduction system into the manufacturing process. The 
economic factors include the cost of the materials needed to execute the viral reduction 
process, the required machinery to complete the necessary processes, and finally the man-
hours required for its successful process fulfillment. It was determined that the cost per 
100 sutures would be less than one dollar, based on the cost of materials once the 
processes are carried out on a larger scale (Appendix B). Additionally, the necessary 
machinery to complete these procedures would be a machine that adds a required amount 
of HCl to the fibrinogen to reach the desired pH level, a lyophilizer, a sonicating bath to 
dissolve the solvent detergent treated fibrinogen, and an oven to provide the final dry heat 
step. The man-hours would be required for adding the ammonium sulfate precipitation 
materials, as well as ensuring that the threads are brought through all of the necessary 
viral reduction steps in a sterile manner. Overall, the addition of this viral reduction 
process will cost a minimal amount in order to get the manufacturing process to meet 
FDA requirements and standards.  
6.3 Environmental Impact 
In terms of environmental impact, the viral reduction system for fibrin 
microthreads will not directly cause a significant impact. However, with the 
incorporation of this design, FDA approval is likely after the inclusion of this safety 
precaution. VitaThreads would expect to produce these threads for commercialization not 
long after FDA approval is achieved. With mass production comes the need for increased 
products, primarily a bovine source. This increase in demand can have both a positive 
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and negative impact on the environment. With an increased need increase for bovine 
sources, an expansion in population, shelter, land, and resources will be required. On the 
contrary, with this enlargement there is a possibility for the development of renewable 
energy sources from produced waste. Although minimal and in the long term, the viral 
reduction system for fibrin microthread sutures will have an impact on the environment.  
6.4 Societal Influence 
With the possibility of future implementation of fibrin microthreads in the 
healthcare field, there is a significant deal of societal impact. The fibrin microthread was 
developed to improve patient quality of life, by providing a better alternative to suture 
products already available on the market. These threads will provide patients with an 
enhanced quality of life by shortening the wound healing period and inducing less 
fibrotic tissue formation. With this option also comes a number of potential applications 
for the sutures throughout the body, whether they be internal or external. All applications 
would improve the quality of patient treatment and thus have a positive impact on the 
well being of the patient and society as a whole.  
6.5 Political Ramifications 
There are no influences from the development of this viral reduction process that 
would have an impact on global politics. Since the usage of VitaSutures has not been 
introduced to the clinical space yet, the threads are only in the research, development, and 
manufacturing process at VitaThreads. Therefore, there would be no current political 
ramifications associated with the fibrin microthreads.  
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6.6 Ethical Concerns 
The incorporation of viral reduction steps into the thread formation process does 
not impose any major ethical concerns. The primary purpose of the design study is to 
better the lives of patients by ensuring safety and positive health effects from the use of 
bovine derived fibrin microthread sutures. However, ethical concerns stem from the 
products used to form these threads, since both the thrombin and fibrinogen components 
are derived from bovine. Additionally, there are some patient cases in which animal 
derived products will not wish to be used due to the preservation of animal rights.  
6.7 Health and Safety Issues 
The addition of a viral reduction system in the manufacturing process will 
improve the safety of the patients treated using fibrin microthread sutures. The 
microthread product is comprised primarily of bovine derived fibrinogen and thrombin. 
With the use of any mammalian-based products, the risk of viral transmission is 
presented to the patient. The fibrin microthreads are currently sterilized to kill bacteria 
and fungi by means of ethylene oxidation, however this method is not effective against 
viruses. With the incorporation of the viral reduction system proposed in this design 
project, viral concentrations are reduced. This viral reduction also minimizes the risk of 
viral transmission to the patient, ultimately increasing the safety of this product. 
Fibrin microthread sutures also improve the health of the receiving patient. These 
threads have been proven to reduce scar tissue formation, as well as increase the wound-
healing rate. By reducing wound healing time, the risk of complications, such as infection 
and wound reopening, is reduced. Scar tissue often times can negatively affect 
surrounding tissues by causing pain and limiting functionality. The reduction of the scar 
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tissue formation, with the use of these fibrin-based sutures, can limit, and in some cases 
eliminate, the risks of these side effects. 
6.8 Manufacturability 
The process established in the proposal for a viral reduction system was designed 
for incorporation into the original manufacturing method. The overall steps for producing 
the fibrin microthreads were not altered, however, additional steps were added to ensure 
patient safety. The fibrinogen and thrombin initially arrive in powder form are dissolved 
in a buffered solution, at which point two viral reduction steps are added. Fibrinogen is 
treated with a solvent detergent and precipitated using ammonium sulfate and the 
thrombin pH is altered to an acid pH at this phase. These solutions are draw up and 
extruded together into a HEPES solution where the threads form. The threads are allowed 
to dry and the viral reduction process is completed with a dry heat treatment. The new 
design process can be carried out solely by human work or can be executed by a 
machine-based process, which would ultimately expedite the manufacturing time. This 
method can also be easily scaled for manufacturing purposes for mass production.  
6.9 Sustainability  
The implementation of the viral reduction system will require the usage of 
machinery to execute the different procedures, in addition to the equipment already in use 
for the production of the fibrin microthread sutures. Therefore, the equipment utilized 
will require a electrical energy input to function, in addition to the man-power to 
complete additional procedures. All of this equipment can be incorporated into the 
already developed manufacturing process and thus will have a minor or nonexistent 
impact on the environment.  
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7.0 Discussion 
The purpose of evaluating the different viral reduction methods for fibrin 
microthread formation, thread mechanics, and cost allowed for the final design to be 
determined. These three outcomes are crucial for both maintaining the original properties 
of the fibrin microthreads and ensuring that the cost is low enough for its integration into 
the current manufacturing process.  
The acid pH treatment is applied to the liquid thrombin during the second step of 
the fibrin microthread manufacturing process. It was recognized that when the thrombin 
was treated for at least five minutes at a pH of 4.00, viral reduction occurred. This 
method of viral reduction is an inexpensive method that can be quickly and easily added 
to the manufacturing process. Typically less than 10 mL of HCl was utilized to pH 
enough thrombin to make a batch of 100 fibrin microthreads. The plaque assay was run to 
determine the viral reduction factor of this specific method and it was determined that a 
viral reduction factor of greater than 6.0 occurred, which is considered to be a highly 
effective step according to FDA standards. The reason that the exact viral reduction 
amount could not be determined was due to a limitation in our maximum bacteriophage 
concentration (108) the minimum detectable limit of the plaque assay. Therefore, this acid 
pH treatment can be viewed as an independent reduction step applied to thrombin and can 
be expected to have a higher viral reduction factor when the method is evaluated by a 
third party for FDA approval.  
The solvent detergent treatment applied to the liquid state of fibrinogen was 
determined to be most effective when the 2X concentration of Triton-X and TNBP were 
applied, as opposed to the normal concentrations and the 5X concentrations. This was 
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further validated using the plaque assay testing, which determined that the solvent 
detergent method causes a viral reduction of 3.6 occurred. This viral reduction level is 
considered to be a moderately effective step according to FDA standards. This solvent 
detergent method can also be viewed as an independent viral reduction step that is 
applied specifically to the fibrinogen. A specific viral reduction value was able to be 
determined for this step because it was above the minimal detectable limit of the plaque 
assay and below the maximum bacteriophage concentration. 
The final fibrin microthread products are exposed to terminal dry heat for thirty 
minutes at 60°C, as a final viral reduction step. This process can likely be implemented at 
any high dry heat temperature between 60°C and 100°C based on our mechanical 
properties data, but 60°C was thoroughly tested for this project due to what was available 
in the lab space. The plaque assay determined that the dry heat procedure results in a viral 
reduction of greater than 2.0, which is considered to be moderately effective according to 
FDA standards. Again, due to the limitations that arise from the usage of the plaque 
assay, the precise viral reduction value is unable to be determined, but it is hypothesized 
that the reduction factor is significantly higher than 2.  
By proving that all three methods incorporated into the final design result in a 
certain level of viral reduction, it was determined that the FDA requirement of two 
independent reduction steps must be applied to the product was met. The ease at which 
these cost efficient methods can be completed, shows that this viral reduction procedures 
can be readily incorporated into the preexisting manufacturing process.  
Lastly, the decision to use a plaque assay for viral reduction quantification was 
chosen due to its ease of use, accuracy, and cost effectiveness. This method allowed 
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numerous trials to run at a low cost, which allowed for many of the different viral 
reduction methods to be tested repeatedly. The team also developed a way to test the total 
viral reduction that occurred in the fully formed fibrin microthread by dissolving three 
threads in plasmin, followed by the usage of the plaque assay. The dissolution of the fully 
formed threads is a newly found method that the team determined functions as desired. 
Overall, the three methods that comprise the final viral reduction system effectively 
achieve the aim of this project and can be easily incorporated into the existing production 
process of fibrin microthread sutures. This process will ensure future patient safety and 
allow for eventual FDA approval of the fibrin microthread sutures.  
 
 
 
 .  
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8.0 Conclusions and Recommendations 
 
This chapter is a summary of the achievements of the design project as well as the 
impacts the project will have in regards to becoming a material approved by the FDA. 
The authors will also discuss a number of recommendations and future directions for the 
advancement of this biomaterial.  
8.1 Conclusions 
 The design team initially set an objective to design a process for viral reduction in 
fibrin microthread sutures. Viral reduction in mammalian derived materials is essential in 
obtaining FDA approval of biologic materials and to ensure patient safety from 
transmissible viruses. Ideally, this method will be easily implemented into the current 
manufacturing system. The group aimed to not only meet FDA standards but also to 
retain 70% of the mechanical properties shown in threads without viral reduction. There 
was also a need for viral concentration validation system for the product. The group was 
successful in designing an effective method to reduce viral concentrations through a 
multistep process. Fibrinogen was treated with a solvent detergent step and thrombin was 
treated with a pH alteration. These two proteins, once treated, were used to form full 
threads. Upon completion, the final product was secondarily treated with dry heat. The 
combination of these methods proved to enhance mechanical properties. Students were 
able to determine total viral reduction through a plaque assay. This project was essential 
for VitaThreads to continue their work with VitaSutures in moving towards clinical 
studies and eventual FDA approval.  
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8.2 Future Recommendations 
 Although the viral reduction system developed in this MQP produced significant 
results that can be incorporated into the fibrin microthread manufacturing process, there 
are additional procedures that need to be completed in order to reach eventual FDA 
approval. In this project bacteriophages that mimic bovine-derived viruses were used, 
since WPI facilities does not allow for biosafety level three and four viruses, such as 
bovine derived viruses, to be tested. Further research by a third party is not only required 
by the FDA to prove the accuracy of the laboratory results, but is also necessary for the 
biosafety level three and four viruses to be tested using this viral reduction system. It has 
been proven by this project that the viral reduction system reduces the viral presence of 
bacteriophages and should be further tested to quantify the viral reduction when tested 
against bovine-derived viruses.  
 There were also limitations associated with the plaque assay used to quantify the 
overall viral reduction. There was a minimum detectable limit associated with the plaque 
assay that we used for quantification, which was set at 102 bacteriophage titer. This 
limitation did not allow for viral concentration readings below this level to be 
determined, thus resulting in a range of viral reduction values rather than precise values. 
In the future PCR could be used instead of a plaque assay to determine exact viral 
reduction values for each method of the final design. PCR was too costly to utilize due to 
the budget of this project, although the method for dissolving fibrin microthreads using 
plasmin can also be implemented when using PCR.  
 With the focus of the three viral reduction methods, in the future this system can 
be easily integrated into the current manufacturing process. The current procedures used 
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for developing fibrin microthreads would remain intact with the addition of the viral 
reduction system, since all three methods can be incorporated into the existing processes. 
The pH alteration treatment and the solvent detergent steps can be added into 
manufacturing when thrombin and fibrinogen are in their liquid-state. Once the treated 
fibrinogen and thrombin are co-extruded to make the final fibrin microthread, a final 
terminal dry heat step can be applied to ensure the desired viral reduction. Overall, the 
current methods utilized for thread formation will not be altered, but rather additional 
viral reduction steps will be thoroughly incorporated to ensure patient safety.  
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Appendices 
Appendix A: Stress/Strain Curves for Mechanical Testing of Viral Removal 
Methods 
A representative stress/strain curve is provided below for each removal method. 
The curves show a linear region, followed by an exponential increase, and another linear 
region before the thread broke at the UTS point. The high frequency noise is a result of 
the machine used for testing; it was not necessary to filter the data, because the UTS and 
strain values were still available.  
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Appendix B: Cost of Materials per 100 Sutures 
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